Response of Multiple Recurrent TaT1 Bladder Cancer to Intravesical Apaziquone (EO9): Comparative Analysis of Tumor Recurrence Rates

Urology

Volumn 73, Issue 5, 2009, Pages 1083-1086

  Jain, Arun ^a   Phillips, Roger M ^b   Scally, Andrew J ^b   Lenaz, Gino ^c   Beer, Mario ^c   Puri, Rajiv ^a  

^a BRADFORD ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

^c Spectrum Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APAZIQUONE; E 09; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE ANATOMY; DRUG DOSE ESCALATION; HUMAN; MULTIPLE CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT RESPONSE; TUMOR RECURRENCE;

ADMINISTRATION, INTRAVESICAL; AZIRIDINES; BIOPSY, NEEDLE; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLEQUINONES; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROBABILITY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 65049084348     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.12.062     Document Type: Article

References (13)

1. Workman P. Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncol Res 6 (1994) 461-475
2. Hendriks H.R., Pizao P.E., Berger D.P., et al. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer 29A (1993) 897-906
3. Dirix L.Y., Tonnesen F., Cassidy J., et al. EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur J Cancer 32A (1996) 2019-2022
4. Pavlidis N., Hanauske A.R., Gamucci T., et al. A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG). Ann Oncol 7 (1996) 529-531
5. Phillips R.M., Loadman P.M., and Cronin B.P. Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. Br J Cancer 77 (1998) 2112-2119
6. Choudry G.A., Stewart P.A., Double J.A., et al. A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9. Br J Cancer 85 (2001) 1137-1146
7. Puri R., Palit V., Loadman P.M., et al. Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer. J Urol 176 (2006) 1344-1348
8. van der Heijden A.G., Moonen P.M., Cornel E.B., et al. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol 176 (2006) 1349-1353
9. Han R.F., and Pan J.G. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer?. A meta-analysis of randomized trials. Urology 67 (2006) 1216-1223
10. Sylvester R.J., Oosterlinck W., and van der Meijden A.P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171 (2004) 2186-2190 quiz 2435
11. Mattioli F., Curotto A., Manfredi V., et al. Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study. Anticancer Res 25 (2005) 2493-2496
12. Tolley D.A., Hargreave T.B., Smith P.H., et al. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br Med J (Clin Res Ed) 296 (1988) 1759-1761
13. Oosterlinck W., Kurth K.H., Schroder F., et al. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149 (1993) 749-752